+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study



Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study



Journal of Gastroenterology and Hepatology 23(6): 861-866



Background and Aim: We assessed whether the two regimens of pegylated alpha-interferon-2b (PEG-IFN-alpha 2b) plus ribavirin and pegylated alpha-interferon-2a (PEG-IFN-alpha 2a) plus ribavirin showed differences in terms of sustained virological response, withdrawal due to side-effects and dose adjustment requirements in the treatment of naive chronic hepatitis C virus (HCV) patients.Methods: A prospective non-randomized, open-label comparison was made of naive HCV-infected patients undergoing standard 24- or 48-week treatment with two PEG-IFN combined with weight-based dosing regimen of ribavirin (PEG-IFN-alpha 2a/ribavirin, n = 91; PEG-IFN-alpha 2b/ribavirin, n = 92).Results: Sustained virological response was similar in PEG-IFN-alpha 2a and PEG-IFN-alpha 2b (65.9% vs 62%, P = 0.64), without differences according to genotype. In 117 patients with HCV genotype 1, the corresponding rates were 50.8% versus 46.6% (P = 0.713). Rapid virological response at 4 weeks, early virological response at 12 weeks and transient virological response were also similar. In the multivariate analysis, HCV genotype (odds ratio [OR] = 0.076, 95% confidence interval [CI] 0.029-0.198, P = 0.000) and presence of steatosis in the liver biopsy (OR = 2.799, 95% CI 1.362-5.755, P = 0.005) were significantly associated with response to antiviral therapy. The rate of withdrawals due to treatment-related adverse events was 13.2% in the group of PEG-IFN-alpha 2a and 10.9% in the group of PEG-IFN-alpha 2b. Dose modification of PEG-IFN was necessary in eight patients given PEG-IFN-alpha 2a and in seven given PEG-IFN-alpha 2b.Conclusion: The two PEG-IFN plus ribavirin have comparable anti-HCV activity as shown by similar percentages of patients with sustained virological response.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 032745019

Download citation: RISBibTeXText

PMID: 18422960

DOI: 10.1111/j.1440-1746.2008.05397.x


Related references

A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C. Journal of Viral Hepatitis 12(3): 292-299, 2005

Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology 49(1): 22-31, 2009

Retreatment with pegylated interferon alpha-2b and ribavirin in patients with chronic hepatitis C non responders to interferon monotherapy or interferon and ribavirin combination A prospective randomized pilote study of two regimens Induction versus reg. Journal of Hepatology 40(Suppl 1): 135, 2004

Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. Journal of Antimicrobial ChemoTherapy 63(6): 1256-1263, 2009

Thymosin Alpha-1 in Combination with Pegylated Interferon and Ribavirin in Chronic Hepatitis C Patients Who have Failed to Prior Pegylated Interferon and Ribavirin Treatment. Gut and Liver 1(1): 87-89, 2007

Treatment with pegylated-interferon alpha-2b +ribavirin in relapsers to standard interferon+ribavirin in chronic hepatitis C Efficacy and safety results from a randomized multicentric French study. Hepatology 36(4 Part 2): 359A, 2002

Comparision Of Pegylated Interferon Alpha 2A & Ribavirin vs. Pegylated Interferon Alpha 2B (Pegintron) & Ribavirin For Treatment Of Recurrent Hepatitis C After Liver Transplantation. Transplantation 82(Suppl 2): 540-541, 2006

Effects of Host and virus related factors on Interferon-alpha+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients. 2011

Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype. Journal of Gastroenterology and Hepatology 28(3): 443-449, 2013

Eicosapentaenoic acid could permit maintenance of the original ribavirin dose in chronic hepatitis C virus patients during the first 12 weeks of combination therapy with pegylated interferon-alpha and ribavirin. A prospective randomized controlled trial. Intervirology 50(6): 439-446, 2007

Eicosapentaenoic acid could permit maintenance of the original ribavirin dose in chronic hepatitis C virus patients during the first 12 weeks of combination therapy with pegylated interferon- alpha and ribavirin: a prospective randomized controlled trial. 2007

Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis. Liver International 31(3): 401-411, 2011

Treatment of chronic hepatitis C in HIV infected patients with pegylated interferon alpha 2B plus ribavirin versus pegylated interferon alpha 2B. Journal of Hepatology 38(Suppl. 2): 132, 2003

A randomized trial of pegylated interferon alpha-2B and ribavirin vs pegylated interferon alone in patients with chronic hepatitis C who have failed standard therapy Interim results after 24 weeks. Gastroenterology 123(1 Suppl.): 77, 2002

Neutralizing antibodies to interferon alpha in chronic hepatitis C patients non-responding to pegylated interferon plus ribavirin retreated to PEG-interferon alpha 2a and ribavirin (ANRS gammatri). 2007